

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
February 2, 2010**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

NovaDel Pharma, Inc.

File No. 1-32177 - CF#24478

NorvaDel Pharma, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 8-K/A filed on December 10, 2009.

Based on representations by NorvaDel Pharma, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

| | |
|--------------|---------------------------|
| Exhibit 10.1 | through October 27, 2014 |
| Exhibit 10.2 | through November 12, 2014 |

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Daniel Greenspan
Special Counsel